The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients.

Pablo Mozas Marc Sorigue Alfredo Rivas-DelgadoAndrea RiveroJuan Gonzalo CorreaCarlos CastilloFerran Nadeu Alex Bataller Eva Giné Tycho Baumann Julio Delgado Neus Villamor Elias Campo Laura Magnano Juan-Manuel Sancho Armondo López-Guillermo

Published in: European journal of haematology (2020)

Follicular lymphoma (FL) is the most frequent indolent B-cell lymphoma. The introduction of immunotherapy has greatly improved outcomes for FL patients, with a median overall survival (OS) now approaching 20 years. However, relapses are continuously seen during follow-up, and responses progressively shorten with each relapse, with a median survival after third-line therapy of 4.8 years.

Keyphrases

free survival
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
stem cells
metabolic syndrome
type diabetes
insulin resistance